Zenas BioPharma (ZBIO) Income towards Parent Company (2023 - 2026)

Zenas BioPharma's Income towards Parent Company history runs 4 years deep, the most recent figure standing at -$81.0 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 141.23% year-over-year to -$81.0 million; the TTM figure through Mar 2026 stood at -$435.8 million (down 161.47% YoY), while the FY2025 annual figure was -$388.4 million, down 140.74% from the prior year.
• Income towards Parent Company was -$81.0 million for Q1 2026 at Zenas BioPharma, up from -$251.1 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $35.6 million in Q3 2023 to a low of -$251.1 million in Q4 2025.
• Historically, Income towards Parent Company has averaged -$56.3 million across 4 years, with a median of -$38.6 million in 2024.
• Biggest YoY gain for Income towards Parent Company was 20.77% in 2025; the steepest drop was 344.22% in 2025.
• A 4-year view of Income towards Parent Company shows it stood at -$24.8 million in 2023, then tumbled by 128.15% to -$56.5 million in 2024, then sank by 344.22% to -$251.1 million in 2025, then soared by 67.75% to -$81.0 million in 2026.
• The last three Income towards Parent Company figures came in at -$81.0 million (Q1 2026), -$251.1 million (Q4 2025), and -$51.5 million (Q3 2025), per Business Quant data.